Exenatide decreases hepatic fibroblast growth factor 21 resistance in non-alcoholic fatty liver disease in a mouse model of obesity and in a randomised controlled trial

What Was Tested

Researchers studied Exenatide in the context of fatty liver & elevated liver enzymes in this randomized controlled trial publication.

The researchers examined the effects of exenatide on FGF21 in patients with type 2 diabetes and in a diet-induced mouse model of obesity (DIO).

Who Took Part

The study group was 2 patients.

The age groups tagged for this paper are adults, middle-aged adults and older adults, both men and women.

How the Study Was Run

In design terms this was a randomized, open-label and parallel-group study.

Because people in this Exenatide study were split into groups at random, differences between the groups are less likely to reflect who happened to join each one.

Everyone knew when Exenatide was being given (open label), which is simpler to run but leaves more room for expectations to affect what is reported.

Groups ran in parallel: each of the patients stayed in one arm throughout.

The timeline in the abstract includes 12 months.

What Was Measured

PubMed files the paper under topics including Diabetes Mellitus, Type 2, Disease Models, Animal, Edema, Exenatide, Fatty Liver, Fibroblast Growth Factors and Hypoglycemic Agents.

What This Means in Plain Language

The paper is a randomized, open-label and parallel-group study of Exenatide in 2 patients in people with fatty liver & elevated liver enzymes over 12 months.

With fewer than 40 people, it is a small study, so it is better read as an early signal for further research than as a settled answer.

Results are reported in around 9 sentences of the abstract; we leave them to the paper itself rather than summarise them.

The publication is from 2011 (Diabetologia), a journal based in Germany.

More context: the Exenatide compound page, Fatty liver & elevated liver enzymes research.